Enzalutamide in Biochemically Recurrent Prostate Cancer

22 Apr 20264 min read0 viewsJournal Feed

GIST

New England Journal of Medicine published a clinical update in Research Highlights on 22 Apr 2026. The item focuses on Enzalutamide in Biochemically Recurrent Prostate Cancer. Review the original article for the full source wording and details.

Clinical Editorial

Summary

New England Journal of Medicine published a clinical update in Research Highlights on 22 Apr 2026.

The item focuses on Enzalutamide in Biochemically Recurrent Prostate Cancer.

Review the original article for the full source wording and details.

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

3 Medical Routines That Older People May Not Need

Research Highlights • 22 May 2026

Disparities in prostate cancer screening practices among general practitioners and urologists (PROSHADE study): A cross-sectional study

Research Highlights • 21 May 2026

Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions (DESTINATION 2): protocol for a randomised, phase II/R-IDEAL2b trial

Research Highlights • 07 May 2026

Dutasteride treatment and its effect on standardized uptake values in prostate-specific membrane antigen-PET imaging: A pilot study

Research Highlights • 06 May 2026

The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1-3 prostate cancer

Research Highlights • 27 Apr 2026

The Arrival Of Digital Twins And In Silico Trials In Drug Development

Research Highlights • 27 Apr 2026

Feed Metadata

Source

New England Journal of Medicine